Biocon Biologics gets Rs 1,125 Cr capital infusion from Goldman Sachs
Biocon has announced that its subsidiary Biocon Biologics has approved a Rs 1,125 Cr investment from Goldman Sachs. This capital injection by Goldman Sachs will enable Biocon Biologics to make prudent investments in R&D, high-quality manufacturing, and establish a global commercial footprint.
The company has one of the largest biosimilars portfolios globally, spanning recombinant human Insulin (rh-Insulin), insulin analogs, monoclonal antibodies, and therapeutic proteins for oncology, immunology and other chronic disease areas.
"We are extremely pleased to welcome a capital injection by Goldman Sachs at this inflection point of Biocon Biologics' journey in its quest for global leadership in providing affordable access through Biosimilar drugs," Biocon Executive Chairperson Kiran Mazumdar-Shaw said.